3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
6
Prostatic Neoplasms
4
Neuroblastoma
4
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Glioblastoma
3
Breast Neoplasms
3
Uveal Melanoma
2
Neoplasms
2
Breast Neoplasms, Male
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Glioma
1
Ependymoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
37
Carboplatin
26
Radiotherapy
23
Cisplatin
19
Paclitaxel
18
Erlotinib Hydrochloride
18
Docetaxel
15
Gemcitabine
14
Pemetrexed
13
Etoposide
12
osimertinib
11
Nivolumab
11
durvalumab
9
atezolizumab
9
Radiosurgery
8
Magnetic Resonance Spectroscopy
8
Cetuximab
7
Specimen Handling
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
Taxes
5
Immunoglobulin G
5
Gefitinib
5
Biopsy
5
Bevacizumab
5
fludarabine
4
Radiation
4
Ipilimumab
4
Disulfides
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lung Neoplasms
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01789099
2024-12-16
UV1-hTERT2012L
Ultimovacs ASA
Phase 1/2
Completed
18 enrolled